A group of members of the House of Representatives told a federal appeals court that the NIH’s planned cap on indirect cost reimbursements disregards Congress’ “exclusive authority to control federal spending” and threatens the discovery …
A group of members of the House of Representatives told a federal appeals court that the NIH’s planned cap on indirect cost reimbursements disregards Congress’ “exclusive authority to control federal spending” and threatens the discovery …
@ 2025 Pharminent. All rights reserved